Swen Hoelder
Affiliations: | 1998- | University of California, Berkeley, Berkeley, CA, United States |
Google:
"Swen Hoelder"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Ludovic Drouin | post-doc | The Institute of Cancer Research | |
| Liam Hudson | post-doc | The Institute of Cancer Research | |
| Paolo Innocenti | post-doc | The Institute of Cancer Research | |
| James Mui | post-doc | The Institute of Cancer Research | |
| Hannah Woodward | post-doc | The Institute of Cancer Research | |
| Jack Cheung | research scientist | The Institute of Cancer Research |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Liu M, Mirza A, McAndrew PC, et al. (2023) Determination of Ligand-Binding Affinity () Using Transverse Relaxation Rate () in the Ligand-Observed H NMR Experiment and Applications to Fragment-Based Drug Discovery. Journal of Medicinal Chemistry |
| Harnden AC, Davis OA, Box GM, et al. (2023) Discovery of an Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones. Journal of Medicinal Chemistry |
| Pierrat OA, Liu M, Collie GW, et al. (2022) Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays. Scientific Reports. 12: 18633 |
| Davis OA, Cheung KJ, Brennan A, et al. (2022) Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors. Journal of Medicinal Chemistry |
| Darby JF, Vidler LR, Simpson PJ, et al. (2020) Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. Scientific Reports. 10: 16000 |
| Bellenie BR, Cheung KJ, Varela A, et al. (2020) Achieving Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. Journal of Medicinal Chemistry |
| Anderhub SJ, Mak GW, Gurden MD, et al. (2019) High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. Molecular Cancer Therapeutics. 18: 1696-1707 |
| Watts E, Heidenreich D, Tucker E, et al. (2019) Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. Journal of Medicinal Chemistry |
| Woodward HL, Innocenti P, Cheung KJ, et al. (2018) Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722). Journal of Medicinal Chemistry |
| Hudson L, Mui J, Vázquez S, et al. (2018) Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept. Journal of Medicinal Chemistry |